Iron Deficiency News and Research

RSS

A deficiency of iron can result from a number of different causes. Inadequate iron in the diet, impaired absorption of iron, and excessive bleeding are all examples of conditions that can lead to iron deficiency.

Women enrolled in WIC program are less likely to introduce their infants to cow's milk

Some low-income mothers are more likely than others to introduce their infants to cow's milk too soon. In doing so, they may put their children at risk of health complications, according to a study by researchers at Penn State and the Institute for Children and Poverty, New York.

30 Jun 2010

AMAG, Takeda provide regulatory and clinical update for Feraheme Injection

AMAG Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited today provided a regulatory and clinical update for Feraheme® (ferumoxytol) Injection for intravenous (IV) use.

29 Jun 2010

June issue of Clinic Women's HealthSource provides overview of anemia

Anemia is not a normal part of aging, yet it's fairly common in older adults and causes frailness, weakness and increased risk of falls. According to Mayo Clinic Women's HealthSource, more than one in 10 older adults has anemia. Twenty percent of women are anemic by age 85.

24 Jun 2010

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Ferring Pharmaceuticals Inc. announced today the U.S. commercial availability of LYSTEDA™ (tranexamic acid) tablets, the only non-hormonal and non-surgical therapy indicated specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). In clinical studies, LYSTEDA significantly reduced menstrual blood loss (MBL) over three and six cycles of use with the reduction seen as early as the first cycle of use.

21 Jun 2010

FAIR-HF study: Ferinject improves renal function in patients with CHF and iron deficiency

Results of a subanalysis from the FAIR-HF study demonstrate that correcting iron deficiency with Ferinject (ferric carboxymaltose) can improve renal function in chronic heart failure patients. Ferinject is an intravenous iron product used to treat iron deficiency and iron deficiency anaemia.

From CSL Ltd 31 May 2010

Rockwell Medical's SFP Phase IIb data accepted for presentation at XLVII ERA-EDTA Congress

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that Phase IIb data for its lead drug candidate Soluble Ferric Pyrophosphate (SFP) have been accepted for presentation at the XLVII European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress, organized in collaboration with the Deutsche Gesellschaft fur Nephrologie (DGfN) in Munich, Germany, June 25-28, 2010.

25 May 2010

GFCF diet shows no significant benefits on the behavior of children with ASD: Study

A popular belief that specific dietary changes can improve the symptoms of children with autism was not supported by a tightly controlled University of Rochester study, which found that eliminating gluten and casein from the diets of children with autism had no impact on their behavior, sleep or bowel patterns.

20 May 2010

Daily dose of iron reduces breath-holding spells in children by 90%: Studies

An estimated one in 20 kids suffer from breath-holding spells, which come when they are upset, in pain or surprised. In some cases, the children twitch and jerk around involuntarily, as if they are having a seizure. Their faces sometimes turn blue or pale and they often faint.

12 May 2010

Study finds familial restless legs syndrome more prominent among French Canadian women

Restless legs syndrome, which causes an irresistible desire to move legs, appears to be a hereditary condition that's more prominent among French Canadian women and may be caused by a combination of genetic influences and environmental effects. According to a large-scale study published in the Archives of Neurology, siblings of people affected by restless legs syndrome are three and a half times more likely to develop the disease.

11 May 2010

Rockwell Medical first-quarter sales up 17.1%

5 May 2010

AMAG Pharmaceuticals reports Feraheme net product revenues of $13.1M for first-quarter 2010

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the first quarter ended March 31, 2010.

28 Apr 2010

Study reveals new marker for predicting patients requiring blood transfusion in ICU

Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.

24 Apr 2010

New research indicates patients may develop anemia after gastric bypass surgery

Morbid obesity is one of the most common causes of morbidity and mortality in Western countries. Roux-en-Y gastric bypass (RYGB) has become a common procedure for achieving short- and long-term weight loss. It has gained great popularity among surgeons and patients in recent years. Long

21 Apr 2010

Researchers report major step forward in effort to understand and engineer protein structure

Researchers in Singapore are reporting this week that they have gleaned key insights into the architecture of a protein that controls iron levels in almost all organisms. Their study culminated in one of the first successful attempts to take apart a complex biological nanostructure and isolate the rules that govern its natural formation.

12 Apr 2010

AMAG Pharmaceuticals, Takeda Pharmaceutical announce Feraheme collaboration

AMAG Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited today jointly announced that the companies have entered into a license, development and commercialization agreement related to Feraheme® (ferumoxytol) Injection for intravenous (IV) use in all therapeutic indications.

1 Apr 2010

AMAG Pharmaceuticals' abstract on ferumoxytol for CKD accepted for presentation at NKF 2010

AMAG Pharmaceuticals, Inc. today announced that one abstract has been accepted for presentation at the National Kidney Foundation 2010 Spring Clinical Meeting being held April 13-17, 2010 in Orlando, FL.

19 Mar 2010

New heart-healthy omega-3 crops on horizon

A new heart-healthy, essential omega-3 fatty acid is about to improve an American pantry staple: soybean oil. The new scientific advance will move biotechnology onto the average consumer's daily radar.

17 Mar 2010

'Anti-gluten pill' needed

In the early 1980s, about one per cent of adults in Finland had gluten intolerance, but the figure has since gone up to two per cent by the 2000s.

5 Mar 2010

AMAG Pharmaceuticals reports fourth-quarter 2009 net product revenues of $12.8M attributable to Feraheme

1 Mar 2010

AMAG Pharmaceuticals releases safety update on Feraheme Injection

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today provided a safety update on Feraheme® (ferumoxytol) Injection for intravenous use.

6 Feb 2010